Cancer Clinical Trial -I-Mab Biopharma-TJ004309STM104

Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer

Drug

TJ004309, Atezolizumab

Phase

Phase I

Condition

Solid tumors, Metastatic Cancer

Keywords

CD73 | NT5E Inhibitor